Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial

Pablo Ryan, José L Blanco, Mar Masiá, Lucio García‐Fraile, María José Crusells, Peré Domingo, Adrián Curran, Robert Güerri‐Fernández, Enrique Bernal, Joaquín Bravo Urbieta, Boris Revollo, Juan Macı́as, Juan Tiraboschi, Rocío Montejano, Concha Amador, Miguel Torralba, Dolores Merino, Vicens Díaz-Brito, Marı́a José Galindo, Sergio Ferra Murcia, Aroa Villoslada, Juan Emilio Losa, Francisco Fanjul, Javier Pérez Stachowski, Joaquim Peraire, Joaquín Portilla, Sara de la Fuente, Carlos Dueñas, María J. Vázquez, Silvana Di Gregorio, Herminia Esteban, Pedro Ignacio Gil, Marta de Miguel, Belén Alejos, Estebán Martínez